Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 101Glioma 43Brain Neoplasms 28Neuroblastoma 25Astrocytoma 19Gliosarcoma 15Sarcoma, Ewing 12Rhabdomyosarcoma 12Neoplasms 12Recurrence 11Medulloblastoma 11Small Cell Lung Carcinoma 8Sarcoma 8Oligodendroglioma 8Melanoma 7Osteosarcoma 6Ependymoma 6Diffuse Intrinsic Pontine Glioma 6Central Nervous System Neoplasms 4Rhabdoid Tumor 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Neoplasm Metastasis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Ganglioneuroblastoma 3Desmoplastic Small Round Cell Tumor 3Colorectal Neoplasms 3

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 26130-nm albumin-bound paclitaxel 25Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20Albumin-Bound Paclitaxel 20olaparib 19Taxes 19Biopsy 19Drug Therapy 16atezolizumab 14Nivolumab 14toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Temozolomide × 1 year × Clear all
NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡